Lexeo Therapeutics, Inc. (LXEO)
2.76
-0.14
(-4.99%)
USD |
NASDAQ |
Nov 06, 10:36
Lexeo Therapeutics Enterprise Value : 23.51M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 23.51M |
| November 04, 2026 | 49.06M |
| November 03, 2026 | 39.62M |
| November 02, 2026 | 35.69M |
| October 30, 2026 | 41.98M |
| October 29, 2026 | 35.69M |
| October 28, 2026 | 41.20M |
| October 27, 2026 | 20.75M |
| October 26, 2026 | 7.389M |
| October 23, 2026 | 15.25M |
| October 22, 2026 | 22.33M |
| October 21, 2026 | 30.98M |
| October 20, 2026 | 32.55M |
| October 19, 2026 | 12.11M |
| October 16, 2026 | 2.672M |
| October 15, 2026 | 12.11M |
| October 14, 2026 | 1.885M |
| October 13, 2026 | 10.53M |
| October 12, 2026 | 34.12M |
| October 09, 2026 | 49.06M |
| October 08, 2026 | 47.49M |
| October 07, 2026 | 55.35M |
| October 06, 2026 | 54.56M |
| October 05, 2026 | 63.21M |
| October 02, 2026 | 72.65M |
| Date | Value |
|---|---|
| October 01, 2026 | 79.72M |
| September 30, 2026 | 60.85M |
| September 29, 2026 | 64.00M |
| September 28, 2026 | 41.98M |
| September 25, 2026 | 55.35M |
| September 24, 2026 | 61.64M |
| September 23, 2026 | 71.86M |
| September 22, 2026 | 115.10M |
| September 21, 2026 | 115.89M |
| September 18, 2026 | 125.32M |
| September 17, 2026 | 123.75M |
| September 16, 2026 | 122.18M |
| September 15, 2026 | 119.82M |
| September 14, 2026 | 126.11M |
| September 11, 2026 | 129.25M |
| September 10, 2026 | 137.90M |
| September 09, 2026 | 147.34M |
| September 08, 2026 | 169.35M |
| September 04, 2026 | 179.57M |
| September 03, 2026 | 175.64M |
| September 02, 2026 | 170.92M |
| September 01, 2026 | 164.63M |
| August 31, 2026 | 169.35M |
| August 28, 2026 | 177.21M |
| August 27, 2026 | 187.43M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.884B |
| Oncolytics Biotech, Inc. | 52.27M |
| Sangamo Therapeutics, Inc. | 38.97M |
| Sarepta Therapeutics, Inc. | 2.113B |
| Anixa Biosciences, Inc. | 89.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.87M |
| Total Expenses (Quarterly) | 25.87M |
| EPS Diluted (Quarterly) | -0.3021 |
| Earnings Yield | -41.94% |
| Normalized Earnings Yield | -41.93 |